On Tuesday, Dyax Corp., a biotherapeutic drug firm, announced that it has managed to bag an approval by the US Food and Drug Administration to market Kalbitor, the company's drug manufactured especially for the treatment of Angioedema, a hereditary genetic disorder, in patients of age group 16 and above.

Characterized by undue accumulation of fluids outside blood vessels in the body, the disease causes extreme swelling in the intestinal tract or airway. As per the company, the medicine is the first injectable treatment for the disorder approved in the US.